<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428632</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-308</org_study_id>
    <nct_id>NCT04428632</nct_id>
  </id_info>
  <brief_title>Oral Berotralstat Expanded Access Program</brief_title>
  <official_title>Expanded Access Program With Oral Berotralstat for the Prevention of Attacks in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This expanded access program will provide access to berotralstat for eligible participants
      with hereditary angioedema in the U.S.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physicians may request access to berotralstat for eligible participants with unmet medical
      need

      Physicians can send email inquiries to access.us@inceptua.com or call 1-888-225-8677

      Patients who may be interested should contact their physician about participation

      Berotralstat (BCX7353) will be available through this expanded access program until it is
      commercially available
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Hereditary Angioedema</condition>
  <condition>HAE</condition>
  <condition>Prophylaxis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berotralstat</intervention_name>
    <description>One 150mg capsule administered orally once daily</description>
    <other_name>BCX7353</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must meet all of the following inclusion criteria to be eligible for participation
        in this program:

          1. At least 12 years of age

          2. Able to provide written, informed consent or assent

          3. Patients with a clinical diagnosis of HAE Type I or II who, in the opinion of their
             treating physician, are expected to benefit from an oral treatment for the prevention
             of angioedema attacks, and who are not eligible or able to access a berotralstat
             clinical trial

          4. Females must use acceptable effective contraception

        Exclusion Criteria

        Patients must meet none of the below exclusion criteria to be eligible for participation in
        this program:

          1. Pregnancy or breast-feeding

          2. Any clinically significant medical condition or medical history that, in the opinion
             of the treating physician, would interfere with the patient's safety

          3. Current infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human
             immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>EAP Program Coordinator</last_name>
    <phone>1-888-225-8677</phone>
    <email>access.us@inceptua.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Berotralstat</keyword>
  <keyword>BCX7353</keyword>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>HAE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

